BioCentury | Jul 10, 2020
Finance
Nkarta’s $252M IPO among biggest preclinical listings ever
Nkarta had already beaten expectations by pricing its upsized IPO at $18, but its triple-digit aftermarket gains provided further evidence that the powerful appetite for new biotech listings extends to preclinical companies. The company more...